Highlights ViaDerma, Inc.

Equities

VDRM

US92555K1016

Market Closed - OTC Markets Other stock markets 03:26:14 2024-06-07 pm EDT			5-day change	1st Jan Change
0.0069 ^USD	+4.55%		0.00%	-34.91%

2023	ViaDerma, Inc. Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product	CI
2023	ViaDerma Announces Intent to Launch New Minoxidil Hair Regrowth Product	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ViaDerma, Inc. Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product	23-03-16	CI
ViaDerma Announces Intent to Launch New Minoxidil Hair Regrowth Product	23-03-08	CI
ViaDerma, Inc. Successfully Completes Quality Control Testing of Its New Vitastem Products	22-09-15	CI
ViaDerma, Inc. Set to Launch Two New and Improved Versions of Its Flagship Product, Vitastem and Vitastem Ultra	21-10-04	CI
ViaDerma, Inc. Provides Updates on Current Business Activities	21-06-24	CI
ViaDerma, Inc. Announces Expansion of Its Current Licensing Agreement	21-06-02	CI
ViaDerma, Inc. Nearing Initial Order from Large Hospital Network	21-05-13	CI
ViaDerma, Inc. Completes a Licensing Agreement with a Group of Affiliate Wound Care Medical Practices Operating in Six States	21-01-21	CI
ViaDerma, Inc. Enters into A $250,000 Initial Sales Agreement with Vage Nigeria Ltd	18-04-24	CI
ViaDerma, Inc. Grants Approval to sell VitaStem(TM) its FDA Registered Topical Antibiotic on Amazon.com and Expands Testing into Major US Hospital Chains to Ramp Up Domestic Sales & Begins Production of New Products	17-11-21	CI
ViaDerma, Inc. Commences Distribution of VitaStem(TM), its FDA Registered Topical Antibiotic, and Looks to Expand its Partnership with Biogenx	17-10-19	CI
ViaDerma, Inc. Receives National Drug Code from the FDA for Prolayed	17-06-27	CI
Viaderma, Inc. Receives Positive Results on Phase I Testing in Canada with its Proprietary THC Delivery and Moves to Phase II Trials and Development of New Products with its MMJ Technologies	17-05-15	CI
Viaderma, Inc. Enters the Sexual Dysfunction Market & Files with the Food and Drug Administration for New OTC Drug to Conquer Premature Ejaculation for Men	17-04-05	CI
ViaDerma, Inc. Signs Licensing and Distribution Agreement with Two Pharmaceuticals Companies for its FDA Registered Drug	17-01-11	CI
ViaDerma, Inc. Announces TetraStem	14-12-09	CI
ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA	14-10-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer